Objectives: To analyze predictive clinical factors of survival in bone-metastatic prostate cancer, and to develop a prognostic nomogram for patients with this condition. Methods: The present study included 392 patients with bone-metastatic prostate cancer treated with androgen deprivation therapy. Pretreatment parameters were analyzed using the Cox proportional hazards model to identify the predictors of overall survival. Covariates -which showed statistical significance on multivariate analysiswere used to develop a nomogram. A linear predictor model was utilized to develop the nomogram. Results: The median overall survival was 40.3 months (95% confidence interval 32.2-48.5). Univariate analysis showed that clinical T stage, Gleason score, initial prostatespecific antigen value and the number of metastatic lesions were independent prognostic factors for overall survival. These predictors remained significant as independent prognostic factors for overall survival after analysis using the multivariate Cox regression model. The nomogram constructed from those prognostic factors showed good discrimination for predicting the 5-year overall survival, with an area under the curve of 0.69. Acceptable agreement of the observed and predicted probabilities was observed in the calibration plot. Conclusions: The present prognostic nomogram might be a useful tool for predicting overall survival in pretreatment bone-metastatic prostate cancer, specifically among Indonesian patients. Further studies are required to provide external validation to support the utilization of this nomogram.
Introduction
Approximately 1.1 million men worldwide were diagnosed with PCa in 2012. PCa is the second most common cancer among men, and currently the fifth leading cause of cancer mortality among men. The incidence of PCa in developed countries is higher compared with developing countries. In Indonesia, 13 663 new cases (14.8/100 000) were diagnosed, and 9191 patients (9.8/100 000) died of PCa in 2012. The increased rate of PCa in Indonesia during the past decade has made this disease the third most common cancer in men after lung and colorectal cancer. 1 The incidence of localized PCa has been increasing, since PSA screening became popular. This reduces the incidence of metastatic PCa. Between 60% and 70% of PCa patients present with non-palpable disease in developed countries. 2 However, this finding is different in Indonesia, with approximately half of patients having metastatic disease at initial diagnosis. 3 Since the introduction of ADT for the treatment of advanced PCa by Huggins and Hodges in 1941, the use of ADT has now become a standard treatment for metastatic PCa. 4, 5 The efficacy of ADT includes prolonged OS, relief of bone pain and improvement of urinary symptoms. Previous retrospective studies showed a great difference in survival, with a median OS of 21-84 months. 6, 7 There are no survival data on metastatic PCa in Indonesia. Our aim was to analyze the survival of hormone-na€ ıve metastatic PCa patients, and to develop a prediction nomogram for OS. This prognostic model might be valuable for patient counseling and decision-making for further treatment.
Methods Patients
The present study analyzed data retrospectively from the standardized medical records for PCa at the Urology Department of Cipto Mangunkusumo Hospital, Jakarta, Indonesia, from January 1995 until December 2014. This retrospective study was approved by the ethics review committee at the Faculty of Medicine, Universitas Indonesia, with ethics number 444/ UN2.F1/ETIK/2016. All patients had metastatic PCa at the time of diagnosis, and none of them had been previously treated. The inclusion criteria were as follows: (i) the diagnosis of adenocarcinoma of the prostate based on a histological examination of transrectal biopsy or transurethral resection of the prostate specimen; (ii) bone metastasis based on bone scans; and (iii) patients treated using ADT. Patients were excluded from the present study if: (i) the time of follow up was <12 months if patients did not die during that time; or (ii) the data were incomplete.
All patients had received ADT (medical or surgical castration). The ADT treatment protocol is based on the EAU Prostate Cancer Guideline. The choice of surgical or medical castration (orchiectomy) was based on patient preference. For medical castration, the patients were treated using a combination of LHRH agonist with anti-androgen to prevent testosterone surge. Patients were included as "continued treatment" as follows: (i) the patients underwent orchiectomy; or (ii) the patients underwent continuous LHRH agonist treatment. If intermittent castration was chosen, the patient had to show clear PSA response during the follow-up period, which was defined as PSA <4 ng/mL. The treatment was resumed when there was a clinical progression or PSA >20 ng/mL. After the development of CRPC, the patient would be categorized to receive either secondary hormonal therapy or cytotoxic chemotherapy.
In the present study, we used TNM clinical staging based on the American Joint Committee on Cancer staging manual 2010. The clinical T was based on digital rectal examination findings or radiological examinations. The pathological grading of PCa was based on GS provided by the International Society of Urological Pathology in 2005. The number of metastatic lesions was based on pathological activity from a bone scan examination. OS was defined as the duration from ADT initiation until death of any causes.
Statistical analysis
The predictive parameters for OS used in the present study were: patient age at initial diagnosis, clinical T stage, serum PSA level and the number of bone lesions. Statistical analysis of the variables was carried out using Statistical Package for Social Sciences (IBM Corporation, Armonk, NY, USA) and R version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria). The Kaplan-Meier method was used to generate actuarial time for the OS. For univariate analysis, the pretreatment parameters to predict OS were tested using the log-rank test. All risk factors with P < 0.25 in univariate analysis were analyzed using a Cox regression analysis for multivariate analysis. All covariates that had a significant value in multivariate analysis were used to develop a prediction nomogram. A P < 0.05 in a two-tailed test was considered statistically significant. These variables were then used for nomogram development. We used the "hdnom" package in R software to construct the nomogram using a linear predictor model. 8 Internal validation of the nomogram was evaluated regarding discrimination and calibration. The bootstrap resampling (200 bootstrap samples) method was undertaken to measure the internal discrimination. The data are presented as timedependent AUC-ROC to evaluate the discrimination ability of the nomogram. The AUC values range was from 0.5 to 1.0, which 0.5 showed no discrimination while 1.0 showed perfect discrimination. Time-dependent AUCs were evaluated between 1 and 5 years. To describe calibration, the predicted and observed probabilities of events at 5 years were plotted across the levels of predicted risk.
Results
A total of 574 metastatic bone-metastatic PCa were examined. Of those patients, just 479 patients were treated using ADT. A total of 87 patients were excluded because of the lack of appropriate data or they did not fulfill the inclusion and exclusion criteria. The remaining 392 patients were enrolled in the present study.
The characteristics of the patients are described in Table 1 . The mean age was 68.3 years (SD 8.64 years), and the majority of patients (66.3%) had GS ≥8. The median initial PSA of this cohort was 116.5 ng/mL. Of the patients, 2.0% (eight patients) had PSA <4 ng/mL. A total of 219 patients (59%) had four or more metastatic bone lesions. In this cohort, the majority of patients (250 patients, 63.8%) were treated with the continuous type of ADT. Of these 250 patients, 170 patients had medical castration using LHRH agonist and 80 patients had an orchiectomy. There was no difference of survival in between the patients who received medical or surgical castration. Of the patients recruited for the present study, 251 patients (64%) died during the followup period. The median follow-up time after diagnosis of metastatic disease was 29 months. During the follow-up period, 24.7% of patients had data for progression to CRPC. Patients who progressed to CRPC still had an ADT treatment. The majority of patients (43.5%) were treated with EMP. There were 13 patients who did not receive any additional treatment for CRPC besides ADT because of poor performance status (nine patients) or they refused any additional treatment (four patients). The median OS was 40.3 months (95% CI 32.2-48.5), the 1-year, 3-year and 5-year OS rates were 84.1%, 40.8% and 22.4%, respectively.
On univariate analysis, clinical T stage, GS, log initial PSA and the number of bone-metastatic lesions appeared as independent prognostic factors for OS. These predictors were still independent factors of OS after analysis using multivariate Cox regression ( Table 2 ). The Kaplan-Meier of OS in several predictors is shown in Figure 1 .
Four parameters that were statistically significant on multivariate analysis were included in developing the prediction nomogram (Fig. 2) . The prediction of 1-, 3-and 5-year OS probability can be calculated by this nomogram. Each of the covariates has a prognostic implication that is represented as "points". The drawing of a vertical line to the points axis determined the points of the covariates. The total points of four predictors were analyzed to gain the total point value. Connecting the vertical line from the total points and survival probability axis determined the probability of survival.
Discrimination ability for the prediction of 5-year OS probability was satisfactory, with AUC 0.69 (IQR 0.682-0.692). However, the prediction ability of 3-year OS had the lowest AUC (AUC 0.66, IQR 0.654-0.666). Figure 3 shows the calibration plot between predicted and observed probabilities of 5-year OS probability. The acceptable agreement of the observed and predicted probabilities was observed in the calibration plot, but potential underestimation was recognized in the patients with better survival.
Discussion
The present analysis of 392 bone-metastatic PCa patients resulted in an OS of 40.3 months. Several studies had been carried out, especially in the Asian population, to determine the survival of bone-metastatic PCa. The OS of 419 bonemetastatic PCa patients analyzed by Teoh et al. was 28 months. 9 Kim et al. found that cancer-specific survival was 65 months. They included 309 metastatic PCa, and the majority of the patients (90%) had bone metastasis. 10 A cohort of 179 men who have non-castration-resistant metastatic PCa treated with ADT showed an OS of 84 months after initiating ADT. 6 The analysis of prognostic survival factors is necessary because of the extensive differences in survival among the population. It might be used by clinicians to predict survival, and to educate patients before and after treatment with ADT.
Almost 40% of the patients in the present study received intermittent ADT. Intermittent ADT was our standard protocol for patients who preferred medical castration. Our protocol was the same as that in the study by Hussain et al. Patients in whom the PSA level was <4 ng/mL after induction therapy were receiving intermittent ADT, and ADT was resumed when the PSA level rose to 20 ng/mL. 11 Evidence suggests that there are no differences in survival with intermittent ADT versus continuous ADT. A meta-analysis carried out by Magnan et al. that included several retrospective and prospective trials showed that intermittent ADT was not inferior to continuous therapy regarding survival. 12 In addition, a systematic review of phase 3 trials showed that mainly in metastatic cases, intermittent ADT could produce oncological results similar to continuous ADT. 13 The present study concluded that GS was associated with OS. Patients with GS 8-10 had a higher HR compared with patients with GS ≥6 (HR 1.54, P = 0.049). Our finding was different from a study by Fig et al. They found no correlation between GS and time to progression or OS in bone-metastatic PCa after hormonal therapy.
14 However, the present finding was consistent with other previous studies. Subsequent analysis by the Southwest Oncology Group Trial 9346 tried to identify the effect of PSA after initiation of ADT. That trial showed that GS was an independent predictor for the risk of death 7 months after induction of ADT. A GS >8 had a >1.5-fold risk of death for those who had a GS <8 (HR 1.58, 95% CI 1.34-1.97, P < 0.01). 15 Bosaily et al. also found that GS was an independent factor for survival in metastatic CRPC. 16 The significance of the number of bone-metastatic lesions on bone scans in influencing survival was shown in the present study. The survival of patients was longer in the group with more than four metastatic lesions compared with those 
The Japanese Urological Association with less than four metastatic lesions (median OS 54 vs 29.1 months). This result is in accordance with several previous studies, which tried to quantify the extent of the bone metastasis. Yahara et al. used positive percentage areas on bone scans that quantified automatically using software for image analysis. Principally, they calculated the positive area by dividing positive areas with the squared area of the bone scan. A decline of the positive area percentage on bone scans was found to be a prognostic factor for survival. 17 Soloway et al. described the classical classification of the area of metastatic-bone lesions. The extent of bone metastasis was classified using Soloway's classification as M1 (fewer than six hotspots), M2 (between 6 and 20 hotspots), M3 (>20 hotspots) and M4 (involvement of 75% of the skeleton). 18 In the non-metastatic condition, the association of PSA and PCa progression was clear. There was a controversial result in the PSA levels for predicting survival among men with hormone-na€ ıve PCa. The suggestion of PSA in the metastatic setting might show the disease burden, as reported in the study by Koo et al. that the PSA value was associated with the number of bone-metastatic lesions. 19 In the present study, high initial PSA showed a poor prognosis for OS. A contrasting result was described by Miyoshi et al. in Japan, which showed that high initial PSA was associated with a better prognosis. Their nomogram showed that a lower PSA level contributed to higher total points, therefore there was a worse prognosis. 20 We analyzed PSA as a continuous variable, which is similar to the Miyoshi et al. nomogram. The J-CAPRA database supports the present findings. Higher initial PSA becomes a poor prognostic value of survival, which shows that a higher PSA contributes to a higher score. However, the J-CAPRA database included patients with localized disease, where the association of PSA and disease progression was clear. Just 43% if patients had advanced and metastatic status, so the J-CAPRA study cannot draw clear conclusions about the relationship between PSA and disease progression in a metastatic setting. 21 Furthermore, the J-CAPRA study analyzed PSA as a categorical variable, which was different to the present study where PSA was analyzed as a continuous variable. Glass et al. analyzed the prognostic factors of survival in metastatic PCa patients treated by orchiectomy plus flutamide or orchiectomy plus a placebo. They found the initial PSA to be a contributing factor for survival of those patients, and they used a PSA of 65 ng/mL as a cut-off to stratify the risk of those patients. Some previous studies found that pretreatment PSA was a predictor of response to ADT, 22, 23 whereas other studies suggested that pretreatment PSA level did not predict the interval to progression to CRPC. 24, 25 In the setting of progressive metastatic PCa after castration, the initial PSA did not correlate with the OS. 26 A total of 62 patients (24.7%) progressed to CRPC status and most of the patients received EMP. As recommended by several guidelines, ADT was still continued after the development of CRPC. EMP was the only choice for CRPC treatment before the introduction of docetaxel in 2007. In 2015, abiraterone acetate was approved in Indonesia and could be used as a modality of CRPC treatment. Until now, only docetaxel is covered by the national health insurance. The use of enzalutamide was approved in early 2018, but the use was very limited because of the high cost. Radium-232 is not available in Indonesia. Table 3 shows the comparability of the Indonesian guideline 27 for the treatment for metastatic CRPC between the EAU 28 and NCCN 27 guidelines. The Indonesian guideline for CRPC treatment was adapted from the American Urological Association guideline, especially for the patient index. 29 The prediction of our nomogram consists of four elements of pretreatment prognostic factors that have significant associations with OS on multivariate analysis. We included pretreatment serum PSA level, clinical T stage, the number of lesions on bone scans and GS. These are the typical parameters that are usually found in the clinical setting of PCa treatment. Several studies have developed a prognostic nomogram in both hormone-na€ ıve PCa 20 and CRPC. 26, 30, 31 A prognostic nomogram developed by Miyoshi et al. from Japan focused solely on patients with bone-metastatic PCa. That study used five parameters of pretreatment parameters; that is, PSA, clinical T stage, GS, the extent of disease from bone scans and age. The present study did not include age as a parameter of prognostic factor because there was no association between age and OS in our patient cohort. 20 Cooperberg et al. carried out an extensive study evaluating the prognosis of patients receiving primary ADT in advanced PCa. 21 They developed the J-CAPRA score from 19 265 Japanese patients, and the score was validated using a database from the Cancer of the Prostate Strategic Urologic Research Endeavor registry. The parameters of PSA, GS, T stage, N stage and M stage were associated with progression-free survival. The difference of J-CAPRA and our nomogram is our interest in the OS prognostic model for patients with hormone-na€ ıve bonemetastatic PCa.
Several risk assessments for metastatic PCa have been developed from clinical trial data. In 2003, Glass et al. analyzed 1076 patients from the Southwest Oncology Group Study 8894. That trial was a randomized trial that evaluated the impact of adding flutamide treatment for patients who underwent orchiectomy. The patients' risk factors were stratified based on performance status, involvement of the axial skeleton, PSA and GS. 32 After the era of docetaxel, Gravis et al. developed a new prognostic model in 2015. The new prognostic model was based on the GETUG-15 phase 3 trial that randomized patients to ADT alone or ADT + docetaxel. They found alkaline phosphatase, GS and pain score were strong predictors for influencing the OS. 33 The present study also included GS and PSA as a predictors of OS. However, we did not analyze alkaline phosphatase and the pain score as in the GETUG-15 trial, nor the location of metastasis as in the SWOG 8894 trial. Our nomogram just focused on bonemetastatic PCa.
There were several limitations of the present study. The first limitation was that our nomogram was developed from a database that included patients treated with either continuous or intermittent ADT. We did not categorize and analyze the is the predicted probability and the y-axis is the actual probability of 5-year OS. Gray line indicates the ideal reference line where the predicted probabilities match with the observed probabilities. The acceptable agreement of the observed and predicted probabilities is seen in this plot; however, this plot shows the underestimation of predicted survival probabilities in the patient with better observed survival probabilities. impact of methods incorporating ADT for the development the nomogram, because we just focused on pretreatment factors that might influence survival. The previous trial showed no difference of OS for patient treated with intermittent versus continuous ADT. The second limitation was that we did not analyze several parameters, namely, performance status, hemoglobin level and alkaline phosphatase that might be associated with OS because of limitations of our database. The third limitation was that we did not carry out external validation for this study. External validation, especially from different centers, is required to improve the utilization of this nomogram.
In summary, the present study found that the median OS of patients with bone-metastatic PCa was 40.3 months. There are four predictors that are significantly associated with OS: clinical T stage, initial PSA, GS and the number of metastatic lesions. The prediction nomogram was developed using those variables, and might be a useful tool for predicting OS in pretreatment bone-metastatic PCa, specifically among Indonesian patients. Further studies are required to provide external validation to support the utilization of this nomogram.
